Pharmaceutical stocks emerged as the top-performing segment on Tuesday, with the Nifty Pharma index rising 1.88% at 09:39 AM IST, significantly outperforming the Nifty 50 and Sensex, which were up just 0.05%.
Dr. Reddy's Laboratories led the Nifty gainers, rising 2.64% to ₹1,324.80. Sun Pharma gained 1.68% to ₹1,894.20, while Cipla advanced 1.22% to ₹1,433, making pharma stocks the top three gainers on the benchmark index.
The rally extended to the broader market, where pharma companies dominated the BSE Midcap gainers list. Emcure Pharmaceuticals surged 5.37%, while Laurus Labs, Gland Pharma, Aurobindo Pharma, Alkem Laboratories and Ipca Laboratories also featured among the top advancing midcap stocks.
The stocks of Indian companies engaged in producing drugs can continue to be an area of concentration in light of the US FDA reaching out to Indian companies to try and overcome the problem of ifosfamide shortage that is used to treat testicular, bladder, and lung cancer. This shows the seriousness of the problem of shortages in the US market and the increasing role of India as a global source of generic drugs.
USFDA Seeks Immediate Supply Of Ifosfamide
Based on the communication through Indian Drug Manufacturers' Association (IDMA), USFDA is looking for manufacturers who can provide ifosfamide injection in 1 g and 3 g formulations. The USFDA requires manufacturers who can supply the drug currently or those who can manufacture ifosfamide injection in 1 g and 3 g formulations.
The USFDA has informed that it prefers products produced by the registered USFDA manufacturing site. On the other hand, the USFDA has also shown willingness to consider non-USFDA registered manufacturing sites which have good record of regulatory compliance. In addition to this, the USFDA has also shown interest in considering products approved and marketed outside the US.
What Triggered The Shortage?
The drug shortage has been associated mainly with the occurrence of a technical problem with a contract manufacturer who manufactures the drug ifosfamide for Baxter International Inc., the primary producer of the drug in the United States.
Though production has been resumed, the manufacturer is operating under capacity, which is not adequate enough to cover the existing demands. The shortage of supply is expected to continue until 2026 due to the manufacturer’s decision to apply a quota allocation system.
According to information from the USFDA dated June 12, several doses of ifosfamide are noted to be unavailable, limited in supply, or temporarily on back order. Supply recovery is expected to occur within October.
Indian Pharma Companies In Focus
The development has thrown several of India’s drug makers into the limelight. Some of the manufacturers of ifosfamide currently include Cipla, Zydus Lifesciences, Alkem Laboratories and GLS Pharma. Zydus has been identified as one of the immediate beneficiaries of the development given that it operates in the ifosfamide market.
Some of the other pharmaceuticals under focus include Aurobindo Pharma owing to its well-established injectable drugs platform, Dr. Reddy’s Laboratories for its oncology API’s & formulations business, Lupin for its capability of producing high-potency oncology products and Sun Pharma due to its scale in oncology & injectables. API manufacturer Aarti Pharmalabs is being seen as a possible indirect beneficiary of the development.
Shares of Cipla were up by 5% to close at ₹1,417 but have since fallen by 5.6% in 2026. On Monday, the stock of Zydus Lifesciences increased by 1.4% to ₹1,085.7 and has climbed by 20% so far this year. The share price of Alkem Laboratories closed flat at ₹5,370 but has dropped by 2% in 2026.
India’s Growing Role In Global Oncology Supply
The Indian pharmaceuticals sector can come to the aid of global drug shortages with more than 10,500 manufacturing units and over 350 pharmaceuticals units registered with the USFDA. India contributes about one-fifth of the global supply of generic drugs and stands third in terms of production worldwide.
The United States is still India’s biggest importer of medicines from India. In FY26, India exported medicines worth ₹75,803.50 crore to the US, which is about 35% of total pharmaceutical exports worth ₹2.18 trillion. Export of anti-cancer drugs to the US was ₹4,356.48 crore out of total anti-cancer drugs exported worth ₹11,430 crore.
As the number of new cancer cases in the US was estimated to be about 2 million in 2025, USFDA’s engagement is a great chance for Indian pharmaceutical companies.
